Marker showed 94% accuracy in patients with indeterminate baseline ACTH levels
— Marker showed 94% accuracy in patients with indeterminate baseline ACTH levels
by Gregory Laub, Senior Director, Video, MedPage Today
July 7, 2026
• 3 min read
At ENDO 2026, the annual meeting of the Endocrine Society, researchers reported that measuring adrenocorticotropic hormone (ACTH) after a 1-mg overnight dexamethasone suppression test (DST) may improve the diagnosis of hypercortisolism in patients whose baseline ACTH levels fall into a common diagnostic gray zone.
Dual testing approach can help in decision making, says researcher
CHICAGO — In a cohort of patients with difficult-to-control type 2 diabetes, approximately one-quarter had hypercortisolism,…
Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
CHICAGO — In a small cohort of patients with Cushing’s disease, most had their urinary free cortisol normalized after being…
CHICAGO — An AI model using electronic health record data helped researchers narrow down who should be screened for primary…
News and commentary from the psychiatry world
The endometriosis ‘hormone fingerprint’ that will pave the way for rapid diagnosis
